Sedana Medical Q2 FY26 EBITDA loss narrows to SEK 1.9 million; net sales fall 1% to SEK 49.1 million

• Sedana Medical posted Q2 net sales of SEK 49.1 million, down 1% year on year.
• EBITDA loss narrowed to SEK 1.9 million from a loss of SEK 4.1 million.
• Net loss narrowed to SEK 9.6 million; loss per share improved to SEK 0.10.
• Submitted a New Drug Application to the FDA in June; expects the FDA to set a PDUFA date in August or September.
• Added a credit facility of up to SEK 50 million as a buffer against potential costs during the FDA review.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sedana Medical AB published the original content used to generate this news brief on July 17, 2026, and is solely responsible for the information contained therein.